Telomir Pharmaceuticals, Inc. (TELO) just unveiled an update.
Telomir Pharmaceuticals, Inc. recently showcased their preclinical data and future study plans at the National Press Club in Washington, D.C. The presentation marked a significant moment for the company as they shared their progress and outlined their research direction. However, the details shared during the event are not to be considered legally filed under securities laws, nor are they to be integrated into any of the company’s future Securities and Exchange Commission filings.
For an in-depth examination of TELO stock, go to TipRanks’ Stock Analysis page.
